Brooklyn ImmunoTherapeutics Accounts Payable

Brooklyn ImmunoTherapeutics posts a accounts payable of $8.8M as of December 2025. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Brooklyn ImmunoTherapeutics's accounts payable was $0. The latest reading is $8.8M (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Brooklyn ImmunoTherapeutics's financial statement story. At $8.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BTX's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Brooklyn ImmunoTherapeutics's other metric pages and overview cover the third.

Judging Brooklyn ImmunoTherapeutics against Telecommunications peers is usually better than using a market-wide rule of thumb. Business models inside Telecommunications are more comparable, which makes gaps in accounts payable easier to interpret. Start with $8.8M here, then scan peer and history charts to see if the gap is persistent.